April 24, 2024, Entinostat Tablets (trade name: Jingzhuda), a Class 1 innovative drug developed by EOC Pharma, was officially approved by the China NMPA[1]https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240430142236103.html. Entinostat Tablets is indicated for combination with aromatase inhibitors for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative locally advanced or metastatic breast cancer that has recurred or progressed after endocrine therapy.
Entinostat is the first innovative drug developed by EOC Pharma. Entinostat works to regulate histone hyper-acetylation and promote transcriptional activation of specific genes by selectively inhibiting class I HDACs, specifically HDAC subtypes 1, 2 and 3, in order to accelerate terminal differentiation and/or induce apoptosis.
The launch of this drug provides a new treatment option for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative locally advanced or metastatic breast cancer.
EOC Pharma’s Entinostat Tablets approved for marketing by China NMPA
About Entinostat
As a novel oral selective histone deacetylase (HDAC) inhibitor, Entinostat is the first class I innovative drug developed by EOC Pharma. It can improve and regulate histone hyper-acetylation and promote transcriptional activation of specific genes by selectively inhibits class I HDAC, especially for representative HDAC subtypes 1, 2 and 3, to inhibit cell proliferation, accelerate terminal differentiation and/or induce apoptosis.
About EOC Pharma[2]https://www.eocpharma.com/p2.html
EOC Pharma is a biotechnology company focusing on the research and development of innovative anti-tumor drugs. Guided by the actual needs of patients, the Company will enter the full commercialization stage through the combination of external technologies and independent R&D and relying on the forward-looking layout ability and improving the new drug development platform. The Company is committed to developing innovative anti-tumor drugs with clinical value and commercial potential, becoming a leading pharmaceutical company in China with comprehensive capabilities of R&D, production and commercialization, and bringing more and better breakthrough treatments for cancer patients in China.
